Drug Delivery
Low temperature sensitive liposome-doxorubicin may improve drug delivery to solid tumors
Published in Drug Week, September 8th, 2006
In a recent report, researchers in the United States conducted a study "to determine the maximum tolerated dose, dose-limiting toxicities, and pharmacokinetic characteristics of doxorubicin encapsulated in a LTSL when given concurrently with local hyperthermia to canine solid tumors. Privately owned dogs with solid tumors (carcinomas or sarcomas) were treated. The tumors did not involve bone and were located at sites amenable to local hyperthermia."
M.L. Hauck and colleagues, North Carolina State University, wrote,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2006-09-08)
More Articles from Drug Week
- Drug Development
Human primary renal cells used as model for toxicity assessment of chemotherapeutic drugs - Osteoarthritis
IDEA reports positive phase III results for targeted analgesic IDEA-033 - Pharmacokinetics
Interactions between simvastatin and omega-3-acid ethyl esters were examined - Systemic Lupus Erythematosus
Human Genome Sciences launches phase III clinical development program for LymphoStat-B - Acute Myeloid Leukemia
Dacogen (decitabine) for Injection receives U.S. orphan drug designation for patients with AML - Addiction Medicine
GABA-mimetic drugs differently affect cocaine-evoked hyperlocomotion and sensitization - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
